Jonas Brinck

Associate Professor

Karolinska Institutet

Sweden

Research Interests

Explore related searches

Professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Jonas Brinck is an Associate Professor at Karolinska Institutet in Sweden. His research primarily focuses on cardiovascular health, specifically the role of lipoprotein(a) in various cardiometabolic conditions and the progression of aortic stenosis. Recent publications include studies on the impact of elevated lipoprotein(a) in familial hypercholesterolemia and the outcomes of cardiovascular events in patients with diabetes. Dr. Brinck's work contributes significantly to understanding cardiovascular risk factors and therapeutic approaches.

Articles (15)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (7)

Oskar Kovamees

Karolinska Institutet

SWEDEN

View details

John Tengbom

Karolinska Institutet

SWEDEN

View details

Paolo Parini

Karolinska Institutet

SWEDEN

View details

Malin Levin

Professor, Head of department

University of Gothenburg

SWEDEN

View details

Björn Eliasson

University of Gothenburg

SWEDEN

View details

Kausik Ray

Professor of Public Health

Imperial College London

UNITED KINGDOM

View details

Zhichao Zhou

Associate Professor

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jonas Brinck

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study

Elevated lipoprotein(a) and progression of aortic stenosis measured by Doppler echocardiography: A population‐based cohort study

Intensive early and sustained lowering of non–high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry

Relation among hypertriglyceridaemia, cardiometabolic disease, and hereditary factors—design and rationale of the Stockholm hyperTRIglyceridaemia REGister study

Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia

Cardiovascular Outcomes in Patients With Both Diabetes and Phenotypic Familial Hypercholesterolemia: A Nationwide Register-Based Cohort Study

Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing.

The protective effect of remote ischemic conditioning is lost in patients with hypercholesterolemia

The red blood cell as a mediator of endothelial dysfunction in patients with familial hypercholesterolemia and dyslipidemia.

Plasma Lipoprotein(a) measured in routine clinical care and the association with incident calcified aortic valve stenosis during a 14-year observational period

Plasma lipoprotein(a) measured in the routine clinical care is associated to atherosclerotic cardiovascular disease during a 14-year follow-up

Altered Vascular Reactivity to Circulating Angiotensin II in Familial Hypercholesterolemia.

Effective cholesterol lowering after myocardial infarction in patients with nephrotic syndrome may require a multi-pharmacological approach: a case report

Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia.

The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes

Collaborators (7)

Oskar Kovamees

John Tengbom

Paolo Parini

Malin Levin

Björn Eliasson

Kausik Ray

Zhichao Zhou

Make your next move.